Dr. Iris Lavon Ph.D.

Iris LavonAppointment: Head, Molecular Neuro-Oncology Laboratory, Gaffin Center for Neuro-oncology

Area of expertise: Cancer, neuro-oncology, molecular biology.

Tel: 02-677712; Email: irisl@hadassah.org.il

 

Selected Research Publications

Abeliovich D, Lerer I, Pashut-Lavon I, Shmueli E, Raas-Rothschild A, Frydman M (1993) Negative expansion of the myotonic dystrophy unstable sequence. Am J Hum Genet 52(6):1175-1181

Abeliovich D, Lerer I, Pashut-Lavon I, Cohen T (1994) Myotonic dystrophy: molecular analysis of Israeli patients. Biomed Pharmacother 48(8-9):373-380

Lerer I, Meiner V, Pashut-Lavon I, Abeliovich D (1994) Molecular diagnosis of Prader-Willi syndrome: parent-of-origin dependent methylation sites and non-isotopic detection of (CA)n dinucleotide repeat polymorphisms. Am J Med Genet 52(1):79-84

Alkalay I, Yaron A, Hatzubai A, Jung S, Avraham A, Gerlitz O, Pashut-Lavon I, Ben-Neriah Y (1995) In vivo stimulation of I kappa B phosphorylation is not sufficient to activate NF-kappa B. Mol Cell Biol 15(3):1294-1301

Yaron A, Hatzubai A, Davis M, Lavon I, Amit S, Manning AM, Andersen JS, Mann M, Mercurio F, Ben-Neriah Y (1998) Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Nature 396(6711):590-594

Lavon I, Goldberg I, Amit S, Landsman L, Jung S, Tsuberi BZ, Barshack I, Kopolovic J, Galun E, Bujard H, Ben-Neriah Y (2000) High susceptibility to bacterial infection, but no liver dysfunction, in mice compromised for hepatocyte NF-kappaB activation. Nat Med 6(5):573-577

Lavon I, Sheinin T, Meilin S, Biton E, Weksler A, Efroni G, Bar-Joseph A, Fink G, Avraham A (2003) A novel synthetic cannabinoid derivative inhibits inflammatory liver damage via negative cytokine regulation. Mol Pharmacol 64(6):1334-1341
Lavon I, Pikarsky E, Gutkovich E, Goldberg I, Bar J, Oren M, Ben-Neriah Y (2003) Nuclear factor-kappaB protects the liver against genotoxic stress and functions independently of p53. Cancer Res 63(1):25-30

Einstein O, Grigoriadis N, Mizrachi-Kol R, Reinhartz E, Polyzoidou E, Lavon I, Milonas I, Karussis D, Abramsky O, Ben-Hur T (2006) Transplanted neural precursor cells reduce brain inflammation to attenuate chronic experimental autoimmune encephalomyelitis. Exp Neurol 198(2):275-284

Levin N, Lavon I, Zelikovitsh B, Fuchs D, Bokstein F, Fellig Y, Siegal T (2006) Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 106(8):1759-1765

Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T (2006) Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial. J Neurooncol 79(2):153-157

Einstein O, Fainstein N, Vaknin I, Mizrachi-Kol R, Reihartz E, Grigoriadis N, Lavon I, Baniyash M, Lassmann H, Ben-Hur T (2007) Neural precursors attenuate autoimmune encephalomyelitis by peripheral immunosuppression. Ann Neurol 61(3):209-218

Lavon I, Zrihan D, Zelikovitch B, Fellig Y, Fuchs D, Soffer D, Siegal T (2007) Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas. Clin Cancer Res 13(5):1429-1437

Lavon I, Fuchs D, Zrihan D, Efroni G, Zelikovitch B, Fellig Y, Siegal T (2007) Novel mechanism whereby nuclear factor kappaB mediates DNA damage repair through regulation of O(6)-methylguanine-DNA-methyltransferase. Cancer Res 67(18):8952-8959

Lavon I, Refael M, Zelikovitch B, Shalom E, Siegal T (2010) Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro Oncol 12(2):173-180

Lavon I, Zrihan D, Granit A, Einstein O, Fainstein N, Cohen MA, Zelikovitch B, Shoshan Y, Spektor S, Reubinoff BE, Felig Y, Gerlitz O, Ben-Hur T, Smith Y, Siegal T (2010) Gliomas display a microRNA expression profile reminiscent of neural precursor cells. Neuro Oncol 12(5):422-433

Amit D, Matouk IJ, Lavon I, Birman T, Galula J, Abu-Lail R, Schneider T, Siegal T, Hochberg A, Fellig Y (2012) Transcriptional targeting of glioblastoma by diphtheria toxin-A driven by both H19 and IGF2-P4 promoters. Int J Clin Exp Med 5(2):124-135

Farassati FI (2012) Novel Therapeutic Concepts in Targeting Glioma. INTECH, [Place of publication not identified]
Fainstein N, Einstein O, Cohen ME, Brill L, Lavon I, Ben-Hur T (2012) Time limited immunomodulatory functions of transplanted neural precursor cells. Glia 61(2):140-149

Cohen E, Avrahami D, Frid K, Canello T, Levy Lahad E, Zeligson S, Perlberg S, Chapman J, Cohen OS, Kahana E, Lavon I, Gabizon R (2013) Snord 3A: a molecular marker and modulator of prion disease progression. PloS one 8(1):e54433